China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that the National Medical Products Administration (NMPA) has approved the initiation of a Phase Ib/II clinical study for its drug candidate SHR-A2009. The study will assess the safety, tolerability, and efficacy of SHR-A2009 as a treatment for advanced solid tumors in combination with adebrelimab (SHR-1316).
Drug Profiles
SHR-A2009 is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 3 (HER3). There are currently no similar products approved anywhere in the world. Adebrelimab, Hengrui’s programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb), was approved in China in March 2023 for the treatment of first-line extensive-stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy.
Study Details
The Phase Ib/II study will provide important data on the safety and efficacy of the combination therapy. Hengrui aims to advance the development of SHR-A2009 as a potential treatment option for patients with advanced solid tumors.-Fineline Info & Tech
Leave a Reply